Your search returned 3 results.

Sort
Results
1.
Intravenous Allogeneic Mesenchymal Stem Cells for Nonischemic Cardiomyopathy: Safety and Efficacy Results of a Phase II-A Randomized Trial. MedStar authors:
  • Epstein, Stephen E
  • Lipinski, Michael J
PMID:
  • 27856497
Year: 2017
Citation:
  • Circulation Research. 120(2):332-340, 2017 Jan 20
Institution:
  • MedStar Health Research Institute
  • MedStar Heart & Vascular Institute
Medline publication type:
  • Journal Article
Form of publication:
  • Journal Article
All authors:
  • Anderson AS, Butler J, Cole RT, Epstein SE, Gheorghiade M, Greene SJ, Kim RJ, Ko YA, Lipinski MJ, Margulies KB, Quyyumi AA, Sikora S, Skopicki HA, Tankovich NI, Wilcox JE
2.
Tumor necrosis factor-alpha inhibitor use for treatment of refractory cardiac sarcoidosis in a patient with left ventricular assist device: Adalimumab use in refractory sarcoidosis in a patient with left ventricular assist device. MedStar authors:
  • Krishnan, Mrinalini
  • Sheikh, Farooq
PMID:
  • 32830024
Year: 2020
Citation:
  • Journal of Heart & Lung Transplantation. 39(12):1504-1505, 2020 12.
Institution:
  • MedStar Heart & Vascular Institute
Medline publication type:
  • Letter
Form of publication:
  • Journal Article
All authors:
  • Cupps TR, Krishnan M, Sheikh FH
3.
Intravenously-Delivered Mesenchymal Stem Cells: Systemic Anti-Inflammatory Effects Improve Left Ventricular Dysfunction in Acute Myocardial Infarction and Ischemic Cardiomyopathy. MedStar authors:
  • Epstein, Stephen E
  • Lipinski, Michael J
  • Luger, Dror
  • Waksman, Ron
  • Westman, Peter C
PMID:
  • 28232595
Year: 2017
Citation:
  • Circulation Research. 120(10):1598-1613, 2017 May 12
Institution:
  • MedStar Health Research Institute
  • MedStar Heart & Vascular Institute
Medline publication type:
  • Journal Article
Form of publication:
  • Journal Article
All authors:
  • Albelda MT, Dimastromatteo J, Epstein SE, Frias JC, Glover DK, Kharazi A, Lipinski MJ, Luger D, Sikora S, Vertelov G, Waksman R, Westman PC
Pages

Powered by Koha